2 Comments
NIH recognizes the significant effects that this emergency is having on NIH-funded clinical trials and other human subjects studies. For details on expanded flexibilities, such as mid-project period extensions and administrative supplements for unanticipated costs, see NOT-OD-20-087.
Are there any guidelines for research involving immuno-compromised animal models? (e.g SCID mice)?
We recommend you consult with your biosafety office.